Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE: 600594)
Health Care · Pharmaceuticals · CN
CN¥3.72
-4.12% today · -20.3% 1Y
Guizhou Yibai Pharmaceutical Co., Ltd. (SHSE: 600594) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $434.06M and employs 4,832 people.
Over the last twelve months the share price has lost 20.3%, trading between 2.85 and 5.27.
Tweenvest scores Guizhou Yibai Pharmaceutical Co., Ltd. across four factors: quality 71/100, value 50/100, growth 11/100. Its strongest factor is quality.
600594 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $434.06M
- Revenue (TTM)
- $229.53M
- P/E
- —
- EPS
- -0.50
- Dividend yield
- —
- Beta (5Y)
- 0.14
- 52-week high
- CN¥5.27
- 52-week low
- CN¥2.85
- Avg volume (3M)
- —
- Shares outstanding
- 784.39M
- Employees
- 4,832
- Next earnings
- —
About Guizhou Yibai Pharmaceutical Co., Ltd.
Guizhou Yibai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that encompasses the full spectrum of activities from researching and developing new drugs to their production and commercialization throughout the country. The company offers a diverse portfolio of medications, available in various dosage forms including capsules, tablets, granules, syrups, liquid injectables (small-volume), lyophilized powder injections, traditional pills, and oral solutions. These therapeutic agents are designed to address a broad range of medical conditions, specifically targeting oncology, cerebrovascular health, respiratory ailments, rheumatic diseases, digestive disorders, pediatric and gynecological illnesses, alongside providing anti-infective, anti-inflammatory, and pain management solutions. Established in 1995, the company maintains its headquarters in Guiyang, China.
- ISIN
- CNE000001H03
- Founded
- 1995
- Listed since
- Mar 23, 2004
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.